E Fund Management Co. Ltd. lowered its position in shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) by 55.2% during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 9,200 shares of the company’s stock after selling 11,352 shares during the quarter. E Fund Management Co. Ltd.’s holdings in Denali Therapeutics were worth $214,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. GAMMA Investing LLC lifted its holdings in Denali Therapeutics by 879.5% during the second quarter. GAMMA Investing LLC now owns 2,057 shares of the company’s stock worth $48,000 after acquiring an additional 1,847 shares during the period. PNC Financial Services Group Inc. raised its stake in shares of Denali Therapeutics by 48.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,486 shares of the company’s stock worth $53,000 after purchasing an additional 807 shares during the period. Fisher Asset Management LLC purchased a new position in shares of Denali Therapeutics in the 4th quarter worth about $59,000. Assetmark Inc. grew its position in Denali Therapeutics by 65.3% during the fourth quarter. Assetmark Inc. now owns 3,550 shares of the company’s stock valued at $76,000 after buying an additional 1,402 shares during the period. Finally, Headlands Technologies LLC purchased a new stake in Denali Therapeutics during the first quarter worth about $88,000. Hedge funds and other institutional investors own 92.92% of the company’s stock.
Insider Activity
In other news, Director Steve E. Krognes sold 30,000 shares of the company’s stock in a transaction on Monday, July 1st. The shares were sold at an average price of $22.12, for a total value of $663,600.00. Following the transaction, the director now owns 34,404 shares of the company’s stock, valued at $761,016.48. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Company insiders own 7.90% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Denali Therapeutics
Denali Therapeutics Stock Up 0.9 %
Shares of NASDAQ DNLI opened at $31.05 on Friday. The company has a market cap of $4.43 billion, a P/E ratio of -32.34 and a beta of 1.37. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $32.13. The business has a 50-day simple moving average of $24.59 and a two-hundred day simple moving average of $21.41.
Denali Therapeutics (NASDAQ:DNLI – Get Free Report) last released its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The firm had revenue of $1.00 million during the quarter, compared to the consensus estimate of $10.00 million. Denali Therapeutics’s revenue was down 99.7% compared to the same quarter last year. During the same quarter last year, the business posted $1.30 earnings per share. Equities research analysts anticipate that Denali Therapeutics Inc. will post -2.54 EPS for the current year.
Denali Therapeutics Company Profile
Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.
Read More
- Five stocks we like better than Denali Therapeutics
- How to Buy Cheap Stocks Step by Step
- Edgewise Therapeutics Soars 50%: Key Reasons Behind the Surge
- What Are Dividend Achievers? An Introduction
- How the Fed’s Rate Cut Could Supercharge These 3 ETFs
- How to Use High Beta Stocks to Maximize Your Investing Profits
- Microsoft Stock: 3 Reasons It’s Ready to Crush Q4
Want to see what other hedge funds are holding DNLI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report).
Receive News & Ratings for Denali Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Denali Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.